WEDNESDAY, Dec. 6, 2023 (HealthDay News) — The addition of immune checkpoint inhibitors to perioperative cancer treatment is associated with increased rates of certain adverse events, researchers said in November According to a paper published online on the 24th, lancet oncology.
Masaru Fujiwara, M.D., Ph.D., from Mount Sinai Beth Israel in New York City, and colleagues aimed to examine how adding immune checkpoint blockers to perioperative treatment affects treatment-related adverse events. , conducted a systematic review and meta-analysis. The data included data from his 28 randomized controlled trials involving 16,976 cancer patients.
The researchers found no significant association between the addition of immune checkpoint inhibitors and increased treatment-related mortality, and this finding was consistent across immune checkpoint inhibitor subtypes. Among 9,864 patients treated with immune checkpoint inhibitors, 40 fatal toxicities were identified, with pneumonia being the most common (15.0%). Thirteen fatal toxicities were identified among 7,112 patients who were not treated with immune checkpoint blockade. The incidence of grade 3-4 treatment-related adverse events, adverse events leading to treatment discontinuation, and treatment-related adverse events of any grade increased with the addition of immune checkpoint inhibitors (odds ratio, 2.73, 3.67 , and 2.60). , Each). Increased rates of treatment-related deaths and grade 3-4 adverse events were seen primarily associated with the design of immune checkpoint inhibitors and placebos used as adjuvant therapy (odds ratio, 4.02, respectively). and 5.31), the incidence was not increased with immune checkpoint inhibitors. Addition of immune checkpoint inhibition in the neoadjuvant setting.
“Our analysis indicates the need for further study of risk factors and identification of appropriate biomarkers to predict both efficacy and toxicity associated with cancer immunotherapy,” Fujiwara said in a statement. mentioned in.
Several authors disclosed relationships with the biopharmaceutical industry.
Summary/Full text (subscription or payment may be required)
Editorial (subscription or payment may be required)